Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Scientists at Baylor College of Medicine, Michael E. DeBakey Department of Surgery discuss research in cancer vaccines
March 25th, 2008
New investigation results, 'Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer,' are detailed in a study published in Molecular Cancer Therapeutics. According to a study from the United States, "Given the high fatality rate of pancreatic cancer, an effective treatment for this devastating disease is urgently needed. We have shown that mesothelin expression was higher in human pancreatic cancer cells than in human pancreatic duct epithelial cells, and mesothelin mRNA was substantially overexpressed in 18 of 21 (86%) clinical pancreatic adenocarcinoma specimens when compared with the surrounding normal tissues." "However, the...
Source: Cancer Weekly (2008-03-25)
|
